Conference Coverage
about 1 month ago
Jamie Michael, MD, discusses MRI and genomics in active surveillanceabout 2 months ago
Matthew Truesdale, MD, on IsoPSA performance with and without mpMRILatest News
Aug 26, 2026 | Opinion
Nicole L. Miller, MD, FACS, on persistent LUTS after BPH treatment
AI system links surgical gestures with postoperative outcomes
Aug 26, 2026
Datopotamab deruxtecan enters phase 3 trial in high-risk muscle-invasive urothelial cancer
Aug 26, 2026
Pearls & Perspectives: From Emergency Medicine to Sexual Medicine, With Jeff Myers, DO
Aug 26, 2026
Davis Viprakasit, MD, FACS, on the growing role of APPs in cystoscopy
Aug 25, 2026
Advertisement
Shorts
0:48
Nocturia in older adults: Understanding its clinical significance
10 hours ago
by
Kari A.O. Tikkinen, MD, PhD
0:35
The case for permanent Medicare payment reform in urology
2 days ago
by
Celeste Kirschner, CAE, MHSA
0:49
The UroOnc Minute: Emphasizing cribriform and IDC reporting in prostate cancer
3 days ago
by
Adam B. Weiner, MD(+1 more)
1:27
The Expert APProach: Leveraging coding to demonstrate APP productivity and value
6 days ago
by
Joy Maulik, CRNP(+1 more)
0:47
Hans Arora, MD, PhD, discusses the role of APPs and nurses in surgical care
6 days ago
by
Hans Arora, MD, PhD
0:25
Early diagnosis and guideline-concordant penile cancer care
7 days ago
by
Luis G. Medina, MD
0:32
IVF-related incontinence: When to reassure vs refer
9 days ago
by
Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, MSCP, HAES
0:36
Adjuvant pembrolizumab in RCC: Counseling patients on long-term toxicity
12 days ago
by
Elizabeth Nally, MBBS
0:46
Testosterone therapy in women: Rethinking pre- and postmenopausal categories
15 days ago
by
Jessica M. Yih, MD
0:21
IVF and voiding symptoms: Start with cycle timing
15 days ago
by
Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, MSCP, HAES
From GSM guidance to HRT reform: A landmark year for women’s health
2025 featured multiple advancements in women's health aimed at enhancing treatment options and awareness.
Inguinal lymph node dissection in penile cancer
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
Inside HoLEP: Irina Jaeger, MD, discusses patient selection and technique
Jaeger emphasizes that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication.
Podcasts
Videos
Urology Times Digital Edition
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
"The overall 0% impact to urology does not help urology practices deal with increasing costs incurred for staff, rent, supplies, and other overhead," write Jonathan Rubenstein, MD, and Mark Painter.
"If 2025 showed us anything, it is the power of combining scientific progress with public engagement," writes Michael S. Cookson, MD, MMHC, FACS.
"Once money is in a Roth IRA, the withdrawal rules depend on whether the funds are contributions, conversions, or earnings," writes Julie Khazan, CFP.
The approval is supported by results from the phase 3 KEYNOTE-905/EV-303 trial.
The ExactVu micro-ultrasound platform demonstrated noninferior detection of clinically significant prostate cancer vs MRI.
"The OBBA includes broad and sweeping changes that will have a profound impact," writes Allan Shen, CFP.
The ENDURE 1 study plans to enroll up to 60 patients with benign ureteric strictures.
The phase 3 PSMAddition trial assessed the combination of 177Lu-PSMA-617 plus ADT/ARPI in an earlier stage of metastatic prostate cancer.
Jaeger emphasized that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication
Continuing Medical Education
Advertisement
All News
Advertisement
A national cohort study found that metabolic syndrome and its components were frequently documented within the first year of concurrent ADT and ARPI therapy for prostate cancer.
Clinicians across four cities weigh ARASEC and ARANOTE trial data, drug interactions, and access barriers in mCSPC treatment decisions.
María Natalia Gandur Quiroga, MD, MSc, highlights treatment selection, negative trials, and implementation in GU oncology as 3 key themes emerging from ASCO 2026.
The phase 2 MODeFIRe-1 trial will evaluate investigational MRT-2359 plus apalutamide in AR-mutated metastatic castration-resistant prostate cancer.
Tyler Seibert, MD, PhD, discusses cribriform and intraductal carcinoma and their implications for risk stratification and treatment selection in prostate cancer.
Water vapor thermal therapy also provided greater QoL improvement vs combination pharmacotherapy while preserving sexual function.
Urology practices should prepare for more than a simple payment cut in 2027, according to Jonathan Rubenstein, MD; and Mark Painter.
Kari Tikkinen, MD, PhD, discusses POISE-3 findings showing tranexamic acid reduced major bleeding without significantly increasing thrombotic events in urologic surgery.
Susanne Quallich, PhD, ANP-BC, NP-C, discusses APP leadership, specialization, professional growth, and expanding the role of APPs in urology.
Mary Dunn, MSN, NP-C, OCN, RN, highlights advances in advanced prostate cancer, including earlier systemic therapy, PSMA-PET, and PARP inhibitors.
Advertisement
Scott Bauer, MD, ScM, discusses an N-of-1 trial showing heterogeneous responses to long-term tamsulosin, identifying older men who may be candidates for deprescribing.
The designations were based on preliminary clinical data with 68Ga-NYM096, including a small, multicenter study presented at ASCO 2026.
Hans Arora, MD, PhD, discusses how communication and collaborative leadership can strengthen teamwork and performance in the operating room.
The phase 2 RadiCaL trial found that adding radium-223 to cabozantinib did not improve skeletal event-free survival in metastatic renal cell carcinoma.
The phase 3 NRG-GU005 trial found SBRT improved bowel quality of life vs MH-IMRT but did not improve urinary outcomes or disease-free survival.
Advertisement
Advertisement
Trending on Urology Times
1
Datopotamab deruxtecan enters phase 3 trial in high-risk muscle-invasive urothelial cancer
2
Pearls & Perspectives: From Emergency Medicine to Sexual Medicine, With Jeff Myers, DO
3
Nicole L. Miller, MD, FACS, on persistent LUTS after BPH treatment
4
Metabolic syndrome frequent during first year of ADT-ARPI therapy for prostate cancer
5